Scynexis Inc (SCYX)

$0.59 0.00 (-0.73%)
Market Cap 24.76M
Revenue (ttm) 3.75M
Net Income (ttm) -21.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -567.73%
Debt to Equity Ratio 0.00
Volume 196,600
Avg Vol 552,608
Day's Range N/A - N/A
Shares Out 41.97M
Stochastic %K 8%
Beta 1.69
Analysts Strong Sell
Price Target $3.67

Company Profile

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to t...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 201 884 5485
Address:
1 Evertrust Plaza, 13th Floor, Jersey City, United States
Kingcrab3333
Kingcrab3333 Nov. 14 at 6:26 PM
$SCYX
0 · Reply
Pommy1
Pommy1 Nov. 14 at 6:20 PM
$SCYX this is wt we need David fuck need to sell the co.enough of his bs.6 yrs too long n ur co is not even a http://dollar.be smart not dum ass
0 · Reply
Pommy1
Pommy1 Nov. 14 at 4:23 PM
$SCYX our turn will come
0 · Reply
pantarei
pantarei Nov. 14 at 4:08 PM
$SCYX What???? Merck to Buy Cidara Therapeutics in $9.2 Billion Deal
1 · Reply
Pommy1
Pommy1 Nov. 14 at 2:54 PM
$SCYX gsk needs to offer a buyout
0 · Reply
Kingcrab3333
Kingcrab3333 Nov. 14 at 6:23 AM
$SCYX
0 · Reply
pjinvestmentco
pjinvestmentco Nov. 12 at 8:19 PM
$SCYX David let's get the stock to 55 cents !!
0 · Reply
Dharmazen
Dharmazen Nov. 12 at 6:30 PM
$SCYX SCHEDULE 13G/A: Statement of Beneficial Ownership by Certain Investors https://d1io3yog0oux5.cloudfront.net/scynexis/sec/0000919574-25-006585/0000919574-25-006585.pdf
1 · Reply
Pommy1
Pommy1 Nov. 12 at 3:36 PM
$SCYX some news for gsk about production should do the rest
0 · Reply
mspacmanbrrr
mspacmanbrrr Nov. 11 at 6:55 PM
$SCYX hit the 6 month.
0 · Reply
Latest News on SCYX
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 4:20 PM EST - 9 days ago

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

Oct 15, 2025, 8:00 AM EDT - 4 weeks ago

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Sep 4, 2025, 8:30 AM EDT - 2 months ago

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:30 PM EDT - 3 months ago

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 28, 2025, 8:30 AM EDT - 6 months ago

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 5:08 PM EDT - 8 months ago

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 6, 2024, 4:30 PM EST - 1 year ago

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Oct 3, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

Jul 23, 2024, 7:00 AM EDT - 1 year ago

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

Apr 30, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 9, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Scynexis: Update Following Restructuring Of GSK Deal

Apr 2, 2024, 10:04 AM EDT - 1 year ago

Scynexis: Update Following Restructuring Of GSK Deal

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 4:01 PM EDT - 1 year ago

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Jan 29, 2024, 5:15 PM EST - 1 year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Jan 8, 2024, 4:00 AM EST - 2 years ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Jan 5, 2024, 8:30 AM EST - 2 years ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Jan 4, 2024, 7:00 AM EST - 2 years ago

JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

Dec 29, 2023, 4:00 AM EST - 2 years ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

Dec 28, 2023, 9:00 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 22, 2023, 7:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Dec 21, 2023, 8:00 AM EST - 2 years ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 19, 2023, 5:30 AM EST - 2 years ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'

Dec 18, 2023, 6:46 PM EST - 2 years ago

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 18, 2023, 6:15 AM EST - 2 years ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 13, 2023, 7:00 AM EST - 2 years ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 8, 2023, 5:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 6, 2023, 7:00 AM EST - 2 years ago

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 4, 2023, 7:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Dec 1, 2023, 6:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

Nov 30, 2023, 8:30 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 29, 2023, 7:50 PM EST - 2 years ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 22, 2023, 11:45 PM EST - 2 years ago

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

IMPORTANT JANUARY DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 21, 2023, 7:00 AM EST - 2 years ago

IMPORTANT JANUARY DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 19, 2023, 11:45 PM EST - 2 years ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 17, 2023, 11:15 AM EST - 2 years ago

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

SCYX STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Scynexis, Inc.

Nov 15, 2023, 1:15 PM EST - 2 years ago

SCYX STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Scynexis, Inc.

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 5:17 PM EST - 2 years ago

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Kingcrab3333
Kingcrab3333 Nov. 14 at 6:26 PM
$SCYX
0 · Reply
Pommy1
Pommy1 Nov. 14 at 6:20 PM
$SCYX this is wt we need David fuck need to sell the co.enough of his bs.6 yrs too long n ur co is not even a http://dollar.be smart not dum ass
0 · Reply
Pommy1
Pommy1 Nov. 14 at 4:23 PM
$SCYX our turn will come
0 · Reply
pantarei
pantarei Nov. 14 at 4:08 PM
$SCYX What???? Merck to Buy Cidara Therapeutics in $9.2 Billion Deal
1 · Reply
Pommy1
Pommy1 Nov. 14 at 2:54 PM
$SCYX gsk needs to offer a buyout
0 · Reply
Kingcrab3333
Kingcrab3333 Nov. 14 at 6:23 AM
$SCYX
0 · Reply
pjinvestmentco
pjinvestmentco Nov. 12 at 8:19 PM
$SCYX David let's get the stock to 55 cents !!
0 · Reply
Dharmazen
Dharmazen Nov. 12 at 6:30 PM
$SCYX SCHEDULE 13G/A: Statement of Beneficial Ownership by Certain Investors https://d1io3yog0oux5.cloudfront.net/scynexis/sec/0000919574-25-006585/0000919574-25-006585.pdf
1 · Reply
Pommy1
Pommy1 Nov. 12 at 3:36 PM
$SCYX some news for gsk about production should do the rest
0 · Reply
mspacmanbrrr
mspacmanbrrr Nov. 11 at 6:55 PM
$SCYX hit the 6 month.
0 · Reply
mspacmanbrrr
mspacmanbrrr Nov. 11 at 6:54 PM
$SCYX all in
1 · Reply
Stmkr
Stmkr Nov. 11 at 4:16 PM
$SCYX Ok I am restarting a position here. Trading at 38% of cash with a 2-year runway and a promising next-generation antifungal, still early stage, but maybe to partner.
1 · Reply
WAARLOCCKONG
WAARLOCCKONG Nov. 11 at 4:04 PM
$SCYX stfu bitch boy bot mfer.
0 · Reply
pjinvestmentco
pjinvestmentco Nov. 11 at 3:33 PM
$SCYX back under 60 cents David
0 · Reply
Pommy1
Pommy1 Nov. 11 at 1:54 PM
$SCYX it about time price should slowly go up.
0 · Reply
RealisticBullz
RealisticBullz Nov. 11 at 11:37 AM
$SCYX stop cross ticking this trash
0 · Reply
WAARLOCCKONG
WAARLOCCKONG Nov. 11 at 11:14 AM
$SCYX $ASST $ALTS $WLFI.X $ASTER.X Let’s see what you’re made of mfer. 11.11.
0 · Reply
WAARLOCCKONG
WAARLOCCKONG Nov. 11 at 11:10 AM
$ALTS $CYCU $CYN $SCYX $VMAR
0 · Reply
WAARLOCCKONG
WAARLOCCKONG Nov. 11 at 11:10 AM
$BYND $GSK $SCYX
0 · Reply
Momo7002momo
Momo7002momo Nov. 10 at 10:07 PM
$YDKG crazy volume $WTO unreal trade $SCYX this one forming a breakout soon
1 · Reply
Momo7002momo
Momo7002momo Nov. 10 at 10:07 PM
$CAN bullish $BYND getting backup $SCYX is breaking out soon
0 · Reply
Momo7002momo
Momo7002momo Nov. 10 at 10:06 PM
$BITF fun to trade $NUAI best one so far $SCYX is forming a break out here !
0 · Reply